The national burden of E-code-identified adverse drug events among hospitalized children using a national discharge database

2011 ◽  
Vol 20 (8) ◽  
pp. 866-878 ◽  
Author(s):  
Namita L. Tundia ◽  
Pamela C. Heaton ◽  
Christina M.L. Kelton
2016 ◽  
Vol 16 (1) ◽  
Author(s):  
Mohammed Gebre Dedefo ◽  
Abraham Haileamlak Mitike ◽  
Mulugeta Tarekegn Angamo

2015 ◽  
Vol 15 (1) ◽  
Author(s):  
Tesfahun Chanie Eshetie ◽  
Bisrat Hailemeskel ◽  
Negussu Mekonnen ◽  
Getahun Paulos ◽  
Alemayehu Berhane Mekonnen ◽  
...  

2021 ◽  
Vol 15 ◽  
pp. 117955652199583
Author(s):  
Hitoshi Iwasaki ◽  
Mio Sakuma ◽  
Hiroyuki Ida ◽  
Takeshi Morimoto

Background: Adverse drug events (ADEs) are a burden to the healthcare system. Preventable ADEs, which was ADEs due to medication errors, could be reduced if medication errors can be prevent or ameliorate. Objective: We investigated the burden of preventable ADEs on the length of hospital stay (LOS) and costs, and estimated the national burden of preventable ADEs in pediatric inpatients in Japan. Methods: We analyzed data from the Japan Adverse Drug Events (JADE) study on pediatric patients and estimated the incidence of preventable ADEs and associated extended LOS. Costs attributable to extended LOS by preventable ADEs were calculated using a national statistics database and we calculated the effect of preventable ADEs on national cost excess. Results: We included 907 patients with 7377 patient-days. Among them, 31 patients (3.4%) experienced preventable ADEs during hospitalization. Preventable ADEs significantly increased the LOS by 14.1 days, adjusting for gender, age, ward, resident physician, surgery during hospitalization, cancer, and severe malformation at birth. The individual cost due to the extended LOS of 14.1 days was estimated as USD 8258. We calculated the annual extra expense for preventable ADEs in Japan as USD 329 676 760. Sensitivity analyses, considering the incidence of preventable ADEs and the length of hospital stay, showed that the expected range of annual extra expense for preventable ADEs in Japan is between USD 141 468 968 and 588 450 708. Conclusion: Preventable ADEs caused longer hospitalization and considerable extra healthcare costs in pediatric inpatients. Our results would encourage further efforts to prevent and ameliorate preventable ADEs.


2022 ◽  
pp. 30-35
Author(s):  
Rowan Elkeshawi ◽  
Katherine Maddox ◽  
Andriana Xenophontos ◽  
Kyle Hampson

The delivery of safe and effective healthcare to pediatric and neonatal patients presents unique challenges to the medication-use system. The diversity of patients within this population and the consequences of ontogeny on pharmacokinetics and pharmacodynamics directly impact the safe use of medications in children and increase the risk of adverse drug events.1 This review will explore the medication-use system for hospitalized children and neonates, discuss vulnerabilities within this system, and provide examples of advancements made to improve the pediatric medication-use system.


2008 ◽  
Vol 42 (4) ◽  
pp. 45
Author(s):  
BRUCE K. DIXON
Keyword(s):  

Sign in / Sign up

Export Citation Format

Share Document